Patel et al. accessed the safety and efficacy of the first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab in patients with metastatic melanoma with disease progression on anti–PD–1 therapy [131]. The gene discussed is PDCD1; the disease is metastatic melanoma.